# A Study of Single and Repeat Dose Administration of UBX0101 in Patients With Osteoarthritis of the Knee

> **NCT04229225** · PHASE1 · COMPLETED · sponsor: **Unity Biotechnology, Inc.** · enrollment: 35 (actual)

## Conditions studied

- Knee Osteoarthritis

## Interventions

- **DRUG:** UBX0101
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT04229225
- **Lead sponsor:** Unity Biotechnology, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-01-23
- **Primary completion:** 2020-09-18
- **Final completion:** 2020-09-18
- **Target enrollment:** 35 (ACTUAL)
- **Last updated:** 2020-10-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04229225

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04229225, "A Study of Single and Repeat Dose Administration of UBX0101 in Patients With Osteoarthritis of the Knee". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04229225. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*